Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 231 to 240 of 275 total matches.

Alpha-L-Iduronidase (Laronidase; Aldurazyme)

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003  (Issue 1168)
and heart disease, and typically die within the first decade from cardiorespiratory failure. Patients ...
Recombinant human α-L-iduronidase (laronidase; Aldurazyme BioMarin/Genzyme), an orphan drug, has been approved by the FDA for enzyme replacement therapy in mucopolysaccharidosis (MPS) type I, a lysosomal storage disorder caused by deficiency of the enzyme. This review describes the disease, treatment, adverse effects and cost.
Med Lett Drugs Ther. 2003 Oct 27;45(1168):88 |  Show IntroductionHide Introduction

Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain

   
The Medical Letter on Drugs and Therapeutics • May 02, 2011  (Issue 1363)
dysfunction such as anorgasmia. Small increases in blood pressure and heart rate have been reported ...
Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia, duloxetine (Cymbalta – Lilly) has now also been approved for treatment of chronic musculoskeletal pain.
Med Lett Drugs Ther. 2011 May 2;53(1363):33-4 |  Show IntroductionHide Introduction

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
following treatment failure include a longer duration of treatment with the same therapy, addition ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

Management of Opioid Withdrawal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018  (Issue 1554)
with congestive heart failure, bradyarrhythmias, or hepatic or renal impairment. Lofexidine should not be used ...
Pharmacologic management of opioid withdrawal symptoms can reduce the intensity of drug craving and improve treatment retention in patients with opioid use disorder who will receive maintenance treatment. Withdrawal management without subsequent maintenance treatment is associated with high rates of relapse, overdose death, and HIV and/or hepatitis C virus infection. Several guidelines on management of opioid withdrawal are available. Maintenance treatment of opioid use disorder was reviewed in a previous issue.
Med Lett Drugs Ther. 2018 Aug 27;60(1554):137-42 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Plaque Psoriasis (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024  (Issue 1712)
; causal relationship not established ▶ New onset and exacerbations of heart failure, pancytopenia ...
View the Comparison Table: Some Drugs for Plaque Psoriasis
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e160-6   doi:10.58347/tml.2024.1712b |  Show IntroductionHide Introduction

Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension

   
The Medical Letter on Drugs and Therapeutics • Sep 22, 2008  (Issue 1295)
with systolic blood pressure (SBP) 160 mm Hg or higher, treatment failure (to reduce SBP by 15% or more ...
Clevidipine (Cleviprex - The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has been available in an IV formulation (Cardene IV) for more than 10 years. Like IV nicardipine, clevidipine will probably be used mainly for urgent treatment of hypertension in intensive care units, operating rooms and emergency departments.
Med Lett Drugs Ther. 2008 Sep 22;50(1295):73-5 |  Show IntroductionHide Introduction

Drugs for Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020  (Issue 1596)
or decreased effective intravascular volume due to diuretic therapy, cirrhosis, or heart failure increases ...
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Med Lett Drugs Ther. 2020 Apr 20;62(1596):57-62 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
) and depression of CNS respiratory drive. Cardiovascular effects include bradycardia and heart block (muscarinic ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Red Yeast Rice

   
The Medical Letter on Drugs and Therapeutics • Sep 07, 2009  (Issue 1320)
coronary events, including nonfatal MI and death from coronary heart disease, was 5.7 ...
Red yeast rice is a food product that has been used in Chinese cooking and medicine for centuries. It is available in the US in a capsule formulation and is often used by patients who want a "natural" product to lower cholesterol.
Med Lett Drugs Ther. 2009 Sep 7;51(1320):71-2 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
, cirrhosis, or heart failure increases the risk of NSAID-induced renal toxicity. Cardiovascular ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction